← Back to Screener
China Pharma Holdings, Inc. (CPHI)
Price$0.67
Favorite Metrics
Price vs S&P 500 (26W)-74.18%
Price vs S&P 500 (4W)14.32%
Market Capitalization$26.84M
All Metrics
P/CF (Annual)181.05x
Book Value / Share (Quarterly)$1.47
P/TBV (Annual)4.25x
Revenue Growth (3Y)-20.03%
Cash Flow / Share (Quarterly)$0.00
Price vs S&P 500 (YTD)-48.69%
Gross Margin (TTM)-3.18%
Net Profit Margin (TTM)-76.91%
EPS (TTM)$-0.75
10-Day Avg Trading Volume0.03M
EPS Excl Extra (TTM)$-0.75
Revenue Growth (5Y)-17.53%
EPS (Annual)$-0.74
ROI (Annual)-12.19%
Gross Margin (Annual)-3.18%
Net Profit Margin (5Y Avg)-61.94%
Cash / Share (Quarterly)$0.02
Revenue Growth QoQ (YoY)8.11%
ROA (Last FY)-10.28%
Revenue Growth TTM (YoY)-8.50%
EBITD / Share (TTM)$-0.52
ROE (5Y Avg)-53.11%
Operating Margin (TTM)-78.16%
Cash Flow / Share (Annual)$0.00
P/B Ratio1.18x
P/B Ratio (Quarterly)0.27x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)7.22x
Net Interest Coverage (TTM)-30.86x
ROA (TTM)-17.05%
EV / EBITDA (TTM)296.13x
EPS Incl Extra (Annual)$-0.74
Current Ratio (Annual)0.32x
Quick Ratio (Quarterly)0.09x
3-Month Avg Trading Volume0.05M
52-Week Price Return-54.52%
EV / Free Cash Flow (Annual)2716.53x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.01
P/S Ratio (Annual)6.48x
Asset Turnover (Annual)0.13x
52-Week High$2.60
Operating Margin (5Y Avg)-58.44%
EPS Excl Extra (Annual)$-0.74
CapEx CAGR (5Y)-30.83%
Tangible BV CAGR (5Y)-34.94%
26-Week Price Return-65.43%
Quick Ratio (Annual)0.09x
13-Week Price Return-50.10%
Total Debt / Equity (Annual)0.15x
Current Ratio (Quarterly)0.32x
Enterprise Value$29.909
Revenue / Share Growth (5Y)-40.04%
Asset Turnover (TTM)0.22x
Book Value / Share Growth (5Y)-30.10%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)2.20x
Pretax Margin (Annual)-76.91%
Cash / Share (Annual)$0.02
3-Month Return Std Dev91.54%
Gross Margin (5Y Avg)-10.70%
Net Income / Employee (TTM)$-0
ROE (Last FY)-14.02%
Net Interest Coverage (Annual)-30.86x
EPS Basic Excl Extra (Annual)$-0.74
P/FCF (TTM)62.81x
Receivables Turnover (TTM)17.50x
EV / Free Cash Flow (TTM)2716.53x
Total Debt / Equity (Quarterly)0.15x
EPS Incl Extra (TTM)$-0.75
Receivables Turnover (Annual)17.50x
ROI (TTM)-21.92%
P/S Ratio (TTM)6.48x
Pretax Margin (5Y Avg)-61.94%
Revenue / Share (Annual)$0.97
Tangible BV / Share (Annual)$0.32
Price vs S&P 500 (52W)-89.61%
Year-to-Date Return-44.74%
5-Day Price Return2.89%
EPS Normalized (Annual)$-0.74
ROA (5Y Avg)-19.63%
Net Profit Margin (Annual)-76.91%
Month-to-Date Return9.61%
Cash Flow / Share (TTM)$-0.04
EBITD / Share (Annual)$-0.52
Operating Margin (Annual)-78.16%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)181.05x
ROI (5Y Avg)-28.41%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.75
P/TBV (Quarterly)266.86x
P/B Ratio (Annual)0.27x
Inventory Turnover (TTM)2.20x
Pretax Margin (TTM)-76.91%
Book Value / Share (Annual)$1.47
Price vs S&P 500 (13W)-52.97%
Beta1.14x
P/FCF (Annual)2437.95x
Revenue / Share (TTM)$0.61
ROE (TTM)-28.66%
52-Week Low$0.50
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CPHIChina Pharma Holdings, Inc. | 6.48x | -8.50% | -3.18% | — | $0.67 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
China Pharma Holding Inc is a pharmaceutical manufacturer focused on treatments for high-incidence and high-mortality diseases in China. The company produces injectable medications, tablets, and capsules, including cephalosporin-based and specialty injectable products.